About caribou biosciences inc - CRBU
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
CRBU At a Glance
Caribou Biosciences, Inc.
2929 7th Street
Berkeley, California 94710
| Phone | 1-510-982-6030 | Revenue | 11.16M | |
| Industry | Biotechnology | Net Income | -148,125,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 11.657% | |
| Fiscal Year-end | 12 / 2026 | Employees | 97 | |
| View SEC Filings |
CRBU Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.307 |
| Price to Book Ratio | 1.238 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.274 |
| Enterprise Value to Sales | 3.26 |
| Total Debt to Enterprise Value | 0.748 |
CRBU Efficiency
| Revenue/Employee | 115,041.237 |
| Income Per Employee | -1,527,061.856 |
| Receivables Turnover | 3.746 |
| Total Asset Turnover | 0.045 |
CRBU Liquidity
| Current Ratio | 5.715 |
| Quick Ratio | 5.715 |
| Cash Ratio | 5.483 |
CRBU Profitability
| Gross Margin | 67.336 |
| Operating Margin | -1,220.486 |
| Pretax Margin | -1,332.333 |
| Net Margin | -1,327.404 |
| Return on Assets | -59.193 |
| Return on Equity | -78.973 |
| Return on Total Capital | -99.145 |
| Return on Invested Capital | -69.507 |
CRBU Capital Structure
| Total Debt to Total Equity | 22.285 |
| Total Debt to Total Capital | 18.224 |
| Total Debt to Total Assets | 15.157 |
| Long-Term Debt to Equity | 21.302 |
| Long-Term Debt to Total Capital | 17.42 |